ClinicalTrials.gg

Program

pamlectabart tismanitin

Its studies are mostly in Multiple Myeloma, led by 2 companies.

Furthest: phase 2, since Apr 23, 20212 company-led studies, 2 open or runningNext primary completion: Mar 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Heidelberg Pharma11 open or runningphase 2since Apr 23, 2021Apr 23, 2021Mar 2028phase 2 · NCT04879043
Huadong Medicine11 open or runningphase 1since Mar 3, 2026Mar 3, 2026none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 23, 2021First study: phase 2 study in Multiple MyelomaNew to Heidelberg PharmaHeidelberg Pharma · NCT04879043 · 78 planned · United States, Germany, Hungary and more
  2. Mar 3, 2026Huadong Medicine’s first study: phase 1 study in Neoplasms, Plasma CellNew to Huadong MedicineHuadong Medicine · NCT07529782 · 15 planned · China

Ahead

  1. Mar 2028Primary completion: phase 2 study in Multiple MyelomaHeidelberg Pharma · NCT04879043

TargetBeta

TNFRSF17 →read by rule
“An antibody-drug conjugate (ADC) consisting of pamlectabart, a humanized immunoglobulin G1-kappa monoclonal antibody against the tumor-associated antigen (TAA) B-cell maturation antigen (BCMA, TNFRSF17) ”NCIt, by rule

Other programs on TNFRSF17

ProgramCompanyFurthest phaseStudies
elranatamabrulePfizerphase 415
linvoseltamabruleRegeneron Pharmaceuticalsphase 413
teclistamabruleJohnson & Johnsonphase 411
belantamab mafodotinruleGlaxoSmithKlinephase 325
Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012FAstraZenecaphase 312
etentamigAbbViephase 311
ramantamigJohnson & Johnsonphase 38
anitocabtagene autoleucelruleGilead Sciencesphase 36
equecabtagene autoleucelrulenanjing-iaso-biotechnology-co-ltdphase 35
Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934Sino Biopharmaceuticalphase 34
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34
Evarucabgene Autoleucelrulenexcella-incphase 32

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07529782Neoplasms, Plasma Cell · China1RecruitingHuadong MedicineJun 30, 202615
NCT04879043Multiple Myeloma · United States, Germany, Hungary and more2RecruitingHeidelberg PharmaMar 202878

How it is read

Names in the registry

  • “HDP-101”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.